Diabetoporosis and Risk of Thrombosis
https://doi.org/10.31550/1727-2378-2023-22-8-51-54
Abstract
Aim. To assess the risk factors for thrombosis in patients with osteoporosis-induced diabetes mellitus.
Key points. Osteoporosis is a common multifactorial disease with a high risk of venous thromboembolic complications (VTEС). This is due to the main pathology — diabetes mellitus, the use of medications for the prevention and treatment of osteoporosis. The main pathogenetic patterns of VTEС development in patients with diabetoporosis are considered. These include hemostasis disorders, the calcification or calcification of blood vessels, drug inducers, age-related estrogen deficiency, etc.
Conclusion. Patients with diabetes mellitus, mainly type 2, on the background of obesity, older age and with osteoporosis have an increased risk of developing VTEС. Thorough examination of patients with thrombosis risk factors and dynamic monitoring of them, individualization and personification of approaches to the treatment of osteoporosis are advisable.
About the Author
E. V. Doskina
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
72nd Botkinsky pr-d, Moscow, 125284
References
1. Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2019;30(1):3–44. DOI: 10.1007/s00198-018-4704-5
2. Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y. et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif. Tissue Int. 2019;104(3):235–38. DOI: 10.1007/s00223-018-00512-x
3. Harris S.S., Nguyen T.V., Howard G.M., Kelly P.J. et al. Genetic and environmental correlations between bone formation and bone mineral density: a twin study. Bone. 1998;22(2):141–5. DOI: 10.1016/s8756-3282(97)00252-4
4. Keen R.W., Hart D.J., Lanchbury J.S., Spector T.D. Association of early osteoarthritis of the knee with a Taq I polymorphism of the vitamin D receptor gene. Arthritis Rheum. 1997;40(8):1444–9. DOI: 10.1002/art.1780400812
5. Kolbin A.S., Kasimova A.R., Gilyarevskiy S.R. Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases. Good Clinical Practice. 2022;4:38–49. (in Russian). DOI: 10.37489/2588-0519-2022-4-38-49
6. Sare G.M., Gray L.J., Bath P.M.W. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 2008;29(16):2031–41. DOI: 10.1093/eurheartj/ehn299
7. Canonico M., Plu-Bureau G., Lowe G.D., Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–31. DOI: 10.1136/bmj.39555.441944.BE
8. Farquhar C.M., Marjoribanks J., Lethaby A., Lamberts Q. et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2005;20(3):CD004143. DOI: 10.1002/14651858.CD004143.pub2
9. Wiegratz I., Kuhl H. Metabolic and clinical effects of progestogens. Eur. J. Contracept. Reprod. Health Care. 2006;11(3):153–61. DOI: 10.1080/13625180600772741
10. Vorozhtsova I.N., Budnikova O.V., Afanasyev S.A., Kondratieva D.S. Influence of type 2 diabetes on the myocardium of patients with ischemic heart disease. Siberian Journal of Clinical and Experimental Medicine. 2018;33(1): 14–20. (in Russian). DOI: 10.29001/2073-8552-2018-33-1-14-20
11. Tokmakova A.Yu., Egorova D.N., Doronina L.P. Foot disorders in diabetes mellitus. Obesity and Metabolism. 2017;14(1):41–7. (in Russian). DOI: 10.14341/OMET2017141-47
12. Cauley J.A., Norton L., Lippman M.E., Eckert S. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 2001;65(2):125–34. DOI: 10.1023/a:1006478317173
13. Zwankenberg S.R., van der Schouw Y.T., Schalkwijk C.G., Spijkerman A.M.W. et al. Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc. Diabetol. 2018;17(1):45. DOI: 10.1186/s12933-018-0691-2
14. Jeffcoate W.J., Rasmussen L.M., Hofbauer L.C., Game F.L. Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia. 2009;52(12):2478–88. DOI: 10.1007/s00125-009-1521-6
15. Dolzhenko A., Richter T., Sagalovsky S. Atherosclerosis, vascular calcification and bone loss (osteoporosis): common pathophysiological mechanisms development of the diseases and research novel drags for dual therapy. Ateroscleroz. 2016;12(4):44–67. (in Russian)
16. Harper E.M., Forde H., Davenport C., Rochfort K.D. et al. Vascular calcification in type-2 diabetes and cardiovascular disease: integrative roles for OPG, RANKL and TRAIL. Vascul. Pharmacol. 2016;82:30–40. DOI: 10.1016/j.vph.2016.02.003
17. Moon A.R., Park Y., Chang J.H., Lee S.S. Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: an observational study. Medicine (Baltimore). 2019;98(10):e14489. DOI: 10.1097/MD.0000000000014489
18. Zhou S., Fang X., Xin H., Li W. et al. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jk/Msx2 signaling pathway. PLoS One. 2013; 8(7):e68987. DOI: 10.1371/journal.pone.0068987
19. Petrikov A.S. Anticoagulant therapy in patients with obesity. Flebologiya. 2022;16(2–2):22–3. (in Russian)
20. Dragoman M.V., Tepper N.K., Fu R., Curtis K.M. et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int. J. Gynaecol. Obstet. 2018;141(3):287–94. DOI: 10.1002/ijgo.12455
21. Roach R.E., Helmerhorst F.M., Lijfering W.M., Stijnen T. et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015;2015(8):CD011054. DOI: 10.1002/14651858.CD011054.pub2
22. Van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J. et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921. DOI: 10.1136/bmj.b2921
23. Anderson F.A. Jr, Spencer F.A. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl.1):I9–16. DOI: 10.1161/01.CIR.0000078469.07362.E6
24. Halil M., Cankurtaran M., Yavuz B.B., Ulger Z. et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann. Pharmacother. 2007;41(1):41–5. DOI: 10.1345/aph.1H506
25. Cummings S.R., Eckert S., Krueger K.A., Grady D. еt al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–97. DOI: 10.1001/jama.281.23.2189
26. Vickers M.R., MacLennan A.H., Lawton B., Ford D. et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239. DOI: 10.1136/bmj.39266.425069.AD
27. Barrett-Connor E., Mosca L., Collins P., Geiger M.J. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 2006;355(2):125–37. DOI: 10.1056/NEJMoa062462
28. Vestergaard P., Schwartz K., Pinholt E.M., Rejnmark L. et al. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos. Int. 2010;21(9):1591–7. DOI: 10.1007/s00198-009-1091-y
Review
For citations:
Doskina E.V. Diabetoporosis and Risk of Thrombosis. Title. 2023;22(8):51-54. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-8-51-54
Views:
8
Email this article 